|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM23246832X |
003 |
DE-627 |
005 |
20231224093041.0 |
007 |
cr uuu---uuuuu |
008 |
231224s2013 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2013.09.008
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0775.xml
|
035 |
|
|
|a (DE-627)NLM23246832X
|
035 |
|
|
|a (NLM)24211714
|
035 |
|
|
|a (PII)S1521-6616(13)00245-3
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Pandolfi, Julieta
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Regulatory and effector T-cells are differentially modulated by Dexamethasone
|
264 |
|
1 |
|c 2013
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 30.12.2013
|
500 |
|
|
|a Date Revised 03.12.2013
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a © 2013.
|
520 |
|
|
|a It is assumed that the ratio between effector T cells (Teff) and regulatory T cells (Tregs) controls the immune reactivity within the T-cell compartment. The purpose of this study was to investigate if Dexamethasone (Dex) affects Teff and Tregs subsets. Dex induced on Tregs a dose and time-dependent apoptosis which resulted in a relative increase of Teff. After TCR activation, Dex induced a strong proliferative inhibition of Teff, but a weaker proliferative inhibition on Tregs. These effects were modulated by IL-2, which not only restored the proliferative response, but also prevented Dex-induced apoptosis. The highest dose of IL-2 prevented apoptosis on all FOXP3+CD4+ T cells. Meanwhile, the lowest dose only rescued activated Tregs (aTregs), probably related to their CD25 higher expression. Because Dex did not affect the suppressor capacity of aTregs either, our results support the notion that under Dex treatment, the regulatory T-cell compartment maintains its homeostasis
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a APCs
|
650 |
|
4 |
|a Apoptosis
|
650 |
|
4 |
|a Cytokines
|
650 |
|
4 |
|a Dex
|
650 |
|
4 |
|a Dexamethasone
|
650 |
|
4 |
|a Effector T cells
|
650 |
|
4 |
|a GC
|
650 |
|
4 |
|a GR
|
650 |
|
4 |
|a Glucocorticoids
|
650 |
|
4 |
|a Regulatory T cells
|
650 |
|
4 |
|a Teff
|
650 |
|
4 |
|a Tregs
|
650 |
|
4 |
|a aTregs
|
650 |
|
4 |
|a activated Tregs
|
650 |
|
4 |
|a antigen presenting cells
|
650 |
|
4 |
|a effector T cells
|
650 |
|
4 |
|a geoMFI
|
650 |
|
4 |
|a geometric mean fluorescence intensity
|
650 |
|
4 |
|a glucocorticoid receptor
|
650 |
|
4 |
|a glucocorticoids
|
650 |
|
4 |
|a rTregs
|
650 |
|
4 |
|a regulatory T cells
|
650 |
|
4 |
|a resting Tregs
|
650 |
|
7 |
|a Anti-Inflammatory Agents
|2 NLM
|
650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
650 |
|
7 |
|a IL2RA protein, human
|2 NLM
|
650 |
|
7 |
|a Interleukin-2
|2 NLM
|
650 |
|
7 |
|a Interleukin-2 Receptor alpha Subunit
|2 NLM
|
650 |
|
7 |
|a Dexamethasone
|2 NLM
|
650 |
|
7 |
|a 7S5I7G3JQL
|2 NLM
|
700 |
1 |
|
|a Baz, Plácida
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fernández, Pablo
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Discianni Lupi, Ailén
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Payaslián, Florencia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Billordo, Luis Ariel
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fainboim, Leonardo
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Arruvito, Lourdes
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 3 vom: 28. Dez., Seite 400-10
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:3
|g day:28
|g month:12
|g pages:400-10
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.09.008
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 149
|j 2013
|e 3
|b 28
|c 12
|h 400-10
|